Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease
Ankur Srivastava,R. Gailer,R. Gailer,Sudeep Tanwar,Sudeep Tanwar,P M Trembling,P M Trembling,Julie Parkes,Alison Rodger,Deepak Suri,Douglas Thorburn,Douglas Thorburn,K. Sennett,S. Morgan,Emmanuel Tsochatzis,Emmanuel Tsochatzis,William Rosenberg,William Rosenberg +17 more
TLDR
It is shown that established blood tests for liver fibrosis can be used in primary care to stratify patients with fatty liver disease, leading to a reduction in unnecessary referrals by 80% and greatly improving the detection of cases of advanced fibrosis and cirrhosis.About:
This article is published in Journal of Hepatology.The article was published on 2019-08-01 and is currently open access. It has received 271 citations till now. The article focuses on the topics: Liver disease & Fatty liver.read more
Citations
More filters
Journal ArticleDOI
Non-alcoholic fatty liver disease
TL;DR: In this paper, a global prevalence of 25% and is a leading cause of cirrhosis and hepatocellular carcinoma, and the leading causes of death in people with NAFLD are cardiovascular disease and extrahepatic malignancy.
Journal ArticleDOI
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
Annalisa Berzigotti,Emmanouil Tsochatzis,Jérôme Boursier,Laurent Castera,Nora Cazzagon,Mireen Friedrich-Rust,Salvatore Petta,Maja Thiele +7 more
TL;DR: In this article, the authors provide the latest update to the EASL Clinical Practice Guidelines on the use of non-invasive tests for the evaluation of liver disease severity and prognosis.
Journal ArticleDOI
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Philip N. Newsome,Philip N. Newsome,Magali Sasso,Jonathan J Deeks,Jonathan J Deeks,Angelo H. Paredes,Jérôme Boursier,Wah-Kheong Chan,Yusuf Yilmaz,Sébastien Czernichow,Ming-Hua Zheng,Ming-Hua Zheng,Vincent Wai-Sun Wong,Michael Allison,Emmanuel Tsochatzis,Quentin M. Anstee,David Sheridan,Peter J Eddowes,Indra Neil Guha,Jeremy F. L. Cobbold,Valérie Paradis,Pierre Bedossa,Véronique Miette,Céline Fournier-Poizat,Laurent Sandrin,Stephen A. Harrison +25 more
TL;DR: The FAST score provides an efficient way to non-invasively identify patients at risk of progressive NASH for clinical trials or treatments when they become available, and thereby reduce unnecessary liver biopsy in patients unlikely to have significant disease.
Journal ArticleDOI
Advancing the global public health agenda for NAFLD: a consensus statement.
Jeffrey V. Lazarus,Henry E. Mark,Quentin M. Anstee,Juan Pablo Arab,Rachel L. Batterham,Laurent Castera,Helena Cortez-Pinto,Javier Crespo,Kenneth Cusi,M. Ashworth Dirac,Sven Francque,Jacob George,Hannes Hagström,Terry T-K Huang,Mona H Ismail,Achim Kautz,Shiv Kumar Sarin,Rohit Loomba,Veronica Miller,Philip N. Newsome,Michael Ninburg,Ponsiano Ocama,Vlad Ratziu,Mary E. Rinella,Diana Romero,Manuel Romero-Gómez,Jörn M. Schattenberg,Emmanuel Tsochatzis,Emmanuel Tsochatzis,Luca Valenti,Luca Valenti,Vincent Wai-Sun Wong,Yusuf Yilmaz,Zobair M. Younossi,Shira Zelber-Sagi +34 more
TL;DR: In this paper, a global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved.
Journal ArticleDOI
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).
Kenneth Cusi,Scott D. Isaacs,Diana Barb,Rita Basu,Sonia Caprio,W. Timothy Garvey,Sangeeta R. Kashyap,Jeffrey I. Mechanick,Marialena Mouzaki,Karl Nadolsky,Mary E. Rinella,Miriam B. Vos,Zobair M. Younossi +12 more
TL;DR: A task force of medical experts developed evidence-based guideline recommendations based on a review of clinical evidence, expertise, and informal consensus, according to established American Association of Clinical Endocrinology protocol for guideline development as discussed by the authors .
References
More filters
Journal ArticleDOI
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
TL;DR: Aliment Pharmacol Ther 2011; 34: 274–285
Journal ArticleDOI
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Paul Angulo,David E. Kleiner,Sanne Dam-Larsen,Leon A. Adams,Einar Björnsson,Phunchai Charatcharoenwitthaya,Peter R. Mills,Jill C. Keach,Heather D. Lafferty,Alisha C. Stahler,Svanhildur Haflidadottir,Flemming Bendtsen +11 more
TL;DR: In a longitudinal study of patients with NAFLD, fibrosis stage, but no other histologic features of steatohepatitis, were associated independently with long-term overall mortality, liver transplantation, and liver-related events.
Journal ArticleDOI
Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
Mattias Ekstedt,Hannes Hagström,Patrik Nasr,Mats Fredrikson,Per Stål,Stergios Kechagias,Rolf Hultcrantz +6 more
TL;DR: NAFLD patients have increased risk of death, with a high risk ofdeath from cardiovascular disease and liver‐related disease, and the NAS was not able to predict overall mortality, whereas fibrosis stage predicted both overall and disease‐specific mortality.
Journal ArticleDOI
The Hawthorne Effect: a randomised, controlled trial
TL;DR: It is found that more intensive follow-up of individuals in a placebo-controlled clinical trial of Ginkgo biloba for treating mild-moderate dementia resulted in a better outcome than minimal follow- up, as measured by their cognitive functioning.
Journal ArticleDOI
Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
Robert J. Wong,Maria Aguilar,Ramsey Cheung,Ramsey Cheung,Ryan B. Perumpail,Stephen A. Harrison,Zobair M. Younossi,Zobair M. Younossi,Aijaz Ahmed +8 more
TL;DR: Patients with NASH are less likely to undergo liver transplantation (LT) andLess likely to survive for 90 days on the waitlist than patients with HCV, ALD, or HCV and ALD.